MedTrace Logo

A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

NCT05266196 · Status: ENROLLING_BY_INVITATION · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-08-01

No results posted yet for this study

Summary

This rollover protocol allows continued access to seclidemstat (SP-2577) for patients who are still receiving clinical benefit on completed or closed Salarius sponsored studies.

Conditions

  • Ewing Sarcoma
  • Myxoid Liposarcoma
  • Desmoplastic Small Round Cell Tumor
  • Extraskeletal Myxoid Chondrosarcoma
  • Angiomatoid Fibrous Histiocytoma
  • Clear Cell Sarcoma
  • Myoepithelial Tumor
  • Low Grade Fibromyxoid Sarcoma
  • Sclerosing Epithelioid Fibrosarcoma

Interventions

DRUG

Seclidemstat

Treatment assigned as per parent protocol

Sponsors & Collaborators

  • Salarius Pharmaceuticals, LLC

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-15
Primary Completion
2025-12-31
Completion
2025-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05266196 on ClinicalTrials.gov